Abstract. It was recently demonstrated that ~80% of Merkel cell carcinomas (MCCs) harbour a novel polyomavirus, Merkel cell polyomavirus (MCPyV). MCPyV has been detected in various human tissue samples. However, previous studies on the prevalence of MCPyV in oral tumours or tumour-like lesions are incomplete. To address this issue, we measured MCPyV DNA quantity using quantitative polymerase chain reaction (qPCR) in 327 oral tumours or tumour-like lesions and 54 jaw tumours or cyst lesions from 381 immunocompetent patients, as well as in 4 oral lesions from 4 immunosuppressed patients. qPCR revealed a low MCPyV prevalence (25/381, 6.6%) with low viral loads (0.00024-0.026 copies/cell) in oral and maxillofacial tumours and tumour-like lesions from immunocompetent patients. The prevalence was 7/176 (4.0%) in invasive squamous cell carcinomas (SCCs) [2/60 (3.33%) SCCs of the tongue, 4/52 (7.7%) SCCs of the gingiva and 1/19 (5.3%) SCCs of the floor of the mouth], 1/10 (10%) in dysplasias, 1/5 (20%) in adenocarcinomas, 2/13 (15.4%) in adenoid cystic carcinomas,
Introduction
Merkel cell polyomavirus (MCPyV) was recently discovered to be associated with Merkel cell carcinoma (MCC), a rare and aggressive type of human skin cancer (1) . MCPyV-induced oncogenesis is considered to be involved in the transformative properties of the MCPyV large T antigen. MCPyV has been detected in MCC patients and appears to play a key role in tumourigenesis; ~80% of MCCs harbour MCPyV (1) . Using quantitative polymerase chain reaction (qPCR), MCPyV has been detected in malignant and benign tumours (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Moreover, certain investigators have reported that low viral loads of MCPyV have also been detected in normal human tissue samples, including skin, liver and respiratory secretions, suggesting that this virus is widespread in the human body (7, 17) . However, previous studies on the frequency of MCPyV infection in oral tumours or tumour-like lesions are partial and incomplete (7, 15) . High viral loads of MCPyV were detected in all saliva samples from 10 patients without cancer (7) .
In previous studies conducted by Hashida et al (16) and Pantulu et al (18) , MCPyV was found to be associated with the pathogenesis of non-small-cell lung cancer and chronic lymphocytic leukemia.
The aim of this study was to determine the prevalence of MCPyV and identify new MCPyV-related tumours or tumour-like lesions in the maxillofacial region, in addition The 381 immunocompetent cases were as follows: 155 common-type invasive squamous cell carcinomas (SCCs) (60 of the tongue, 52 of the gingiva, 11 of the buccal mucosa, 19 of the floor of the mouth, 9 of the palate and 4 of the lip), 21 variant-type invasive SCCs (3 spindle cell carcinomas and 18 undifferentiated carcinomas), 3 SCCs in situ, 10 dysplasias, 1 small-cell carcinoma, 5 adenocarcinomas, 13 mucoepidermoid carcinomas, 5 malignant pleomorphic adenomas, 6 malignant melanomas, 10 non-Hodgkin's lymphomas, 6 metastatic cancers (1 case each of esophageal, gastric, renal and prostate cancer, and 2 cases of lung cancer), 11 fibromas, 12 papillomas, 10 lipomas, 5 neurofibromas, 3 Schwannomas, 14 pleomorphic adenomas, 12 Warthin's tumours, 11 pyogenic granulomas, 1 epulis from an MCPyV-positive MCC patient, 14 radicular cysts, 10 dentigerous cysts, 10 keratocystic odontogenic tumours, 12 ameloblastomas, 3 ossifying fibromas and 5 fibrous dysplasias.
Materials and methods

Human
The 4 immunocompromised cases included 1 dysplasia from a bone marrow transplant patient, 1 papilloma from a bone marrow transplant patient, 1 ulcer from a bone marrow transplant patient and 1 ranula from an HIV-positive patient.
The study protocol was approved by the Institutional Review Board of the Faculty of Medicine, Tottori University.
qPCR. DNA was extracted from each sample. Tumour samples sectioned into 10-µm slices were excised into three pieces. DNA was extracted from each sample using the QIAamp DNA FFPE Tissue kit and Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The presence of adequate DNA in the samples was confirmed by measuring the internal control DNA of RNase P. To determine the MCPyV DNA quantity [relative ratio to MCPyV DNA (1.0 copy/cell) from the reference MCC] for each case, qPCR was performed using an ABI PRISM 7900HT Sequence Detection system (Applied Biosystems, Foster City, CA, USA). A total of 30 ng of each DNA sample were amplified using 5 µl of Express qPCR Supermix with Premixed ROX (Invitrogen, Carlsbad, CA, USA), 240 nmol/l fluorescein-labelled locked nucleic acid hydrolysis probe 22 (5'-TGGTGGAG-3') from a Universal Probe Library (Roche Diagnostics, Basel, Switzerland) and 0.9 µmol/l primer in a final volume of 10 µl. The positive control was MCCs, whereas water was used as the negative control. Thermal cycling consisted of incubation for 2 min at 50˚C, with initial denaturation for 10 min at 95˚C, followed by 40 cycles of denaturation for 15 sec at 95˚C and annealing for 1 min at 60˚C, as previously described (19) . The virus quantity was determined using the virus signal in a positive MCC sample as reference. Thresholds were plotted against each standard sample. All the reactions of samples and controls were performed in triplicate, and the average was described. The MCPyV DNA quantity in each sample was determined based on the corresponding standard curves.
Results
MCPyV DNA detection in tumours and tumour-like lesions in the oral cavity and jaws of immunocompetent patients.
MCPyV DNA was quantified from the FFPE samples of 381 immunocompetent and 4 immunocompromised cases and the data are summarised in Tables I and II, respectively. qPCR data for MCPyV DNA are shown for the positive control (Fig. 1A ) and 2 representative cases (Fig. 1B and C) . The range of the MCPyV DNA quantity was very low or low: 0.00024-0.026 copies/cell, with a median of 0.00053 copies̸cell. The overall prevalence of MCPyV in tumours or tumour-like lesions of the oral cavity and jaws was 25/381 (6.6%).
Prevalence of MCPyV in oral tumour or tumour-like lesions.
The MCPyV prevalence in invasive SCCs was 7/176 (4.0%) Warthin's tumours and 2/11 (18.2%) in pyogenic granulomas. The MCPyV DNA (0.00083-0.026) in a case of lipoma was higher compared with that in other tumours or tumour-like lesions.
Prevalence of MCPyV in jaw tumours or cyst lesions. The
MCPyV prevalence was 1/14 (7.1%) in radicular cysts and 1/12 (8.3%) ameloblastomas. No significant difference was observed between the MCPyV prevalence in tumours or tumour-like lesions of the oral cavity and that in tumours or cysts of the jaws (7.0 and 3.7%, respectively; P=0.5537).
MCPyV DNA detection in oral lesions from immunosuppressed patients. MCPyV DNA was detected in one case of papilloma from a bone marrow transplant patient but was not detected in the remaining 3 cases (1/4, 25%) (Table II) .
Discussion
In this study, qPCR was used to investigate whether MCPyV was present in oral and maxillofacial tumours and tumour-like lesions. The possibility of contamination was unlikely, as ultrapure water-negative controls were consistently negative. Loyo et al (7) reported data on MCPyV DNA prevalence in oral cavity fresh-frozen materials (51/67, 76%); the prevalence was 19/47 SCCs, 2/10 normal mucosal samples and 10/10 saliva samples from patients without cancer. Oral cavity samples had 0.026 copies/genome, while MCCs had an average of 10 copies/genome (range, 173-0.05 copies̸genome) and saliva had an average of 0.128 copies/genome (range, 5-0.01) (7). Matsushita et al (17) did not detect MCPyV DNA in non-neoplastic tissues from 10 tongue samples and 2 salivary gland samples from FFPE sections of autopsy cases. The MCPyV prevalence in the present study was 7.0% (23/327). Matsushita et al (17) and our study used FFPE samples for MCPyV quantification, whereas Loyo et al (7) used fresh-frozen tissues. This is a major reason for the differences between our data on prevalence and those reported by Loyo et al (7) . Certain previous studies reported that MCPyV DNA detection in fresh-frozen tissues is more reliable compared with detection in FFPE samples (20) (21) (22) . In this study, low or very low levels of MCPyV DNA were present in a wide variety of oral and maxillofacial tumours and tumour-like lesions, while the reference MCC sample had 1 copy of MCPyV/cell. The MCPyV DNA ratio in oral and maxillofacial tumours and tumour-like lesions relative to the reference MCC ranged between 0.00024 and 0.026, indicating that tumours and tumour-like lesions positive for MCPyV DNA had lower viral loads compared with those of the MCC sample. These very low MCPyV DNA quantities detected in this study suggest the absence of MCPyV-associated tumours or tumour-like lesions in the oral and maxillofacial regions, as the low detected levels of MCPyV DNA may be derived from background non-neoplastic tissues with mild MCPyV infection, rather than from neoplastic tissues.
Cutaneous SCC is the second most frequent type of skin cancer (23) , and cervical SCC is the major type of uterine cervical cancer (14) . In SCC of the skin or uterine cervix, absence or lower frequency of MCPyV has been detected compared with MCCs (9-14). Dworkin et al reported that MCPyV was present in 15% cases of cutaneous SCCs from immunocompetent individuals; this indicates that the pathogenic relevance of MCPyV in SCC is unknown (9). Murakami et al reported that MCPyV was present in 13% cases of cutaneous SCCs from Japanese patients; this indicates that cutaneous SCC in Japanese patients is infrequently associated with MCPyV (13). Imajoh et al reported that MCPyV was present in 19% of cervical SCCs from Japanese patients; this suggested that MCPyV may be a cofactor of human papillomavirus for tumour initiation and/or progression (14) .
Oral SCC is the major type of oral cancer. Loyo et al detected low levels of MCPyV DNA in 19/47 oral SCCs and suggested that MCPyV was derived from background tissues and was not associated with oral SCC.
In this study, the prevalence of MCPyV (23/327, 7.0%) in tumours or tumour-like lesions of the oral cavity was higher compared with that in tumours or cysts of the jaws (2/54, 3.7%). However, the difference was not statistically significant (P=0.5537, Fisher's exact test).
Baez et al (15) reported that MCPyV was present in 36.7% samples of saliva and 21.4% oral tissue samples from immunosuppressed patients. In this study, MCPyV was present in 25% of immunosuppressed patients, which was compatible with the prevalence data of Baez et al (15) . It is evident that our estimated prevalence (1/4, 25%) was higher compared with that for oral or jaw lesions from immunocompetent patients (25/381, 6.6%; P=0.2448, Fisher's exact test). In the present study, prevalence was investigated in only 4 cases from immunosuppressed patients. Therefore, further studies using a large number of cases are required.
In conclusion, the prevalence of MCPyV DNA in FFPE samples of oral and maxillofacial tumours and tumour-like lesions was estimated using qPCR, revealing a low MCPyV prevalence (25/381, 6.6%) with very low or low viral loads (0.00024-0.026 copies/cell) in oral and maxillofacial tumours and tumour-like lesions from immunocompetent patients, and also reconfirmed a high prevalence (1/4, 25%) in oral lesions from immunosuppressed patients. To the best of our knowledge, this study was the first to report prevalence data on MCPyV DNA in tumours and cysts of the jaws (2/54, 3.7%). These data suggest that the detected MCPyV DNA was derived from non-neoplastic background tissues with widespread low-level MCPyV infection, and the presence of MCPyV-related tumourigenesis was not confirmed in oral and maxillofacial tumours and tumour-like lesions. However, these prevalence study data may provide valuable insights for further studies on MCPyV infection and MCPyV-related diseases in the oral and maxillofacial regions.
